A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 4,881,125 shares of AURA stock, worth $40 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
4,881,125
Previous 4,885,000 0.08%
Holding current value
$40 Million
Previous $36.9 Million 17.76%
% of portfolio
0.08%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.9 - $10.36 $26,737 - $40,145
-3,875 Reduced 0.08%
4,881,125 $43.5 Million
Q2 2024

Aug 14, 2024

BUY
$6.81 - $7.89 $2.86 Million - $3.31 Million
420,000 Added 9.41%
4,885,000 $36.9 Million
Q1 2024

May 15, 2024

BUY
$7.09 - $9.24 $1.7 Million - $2.22 Million
240,000 Added 5.68%
4,465,000 $35.1 Million
Q4 2023

Feb 14, 2024

BUY
$7.02 - $11.98 $9.48 Million - $16.2 Million
1,350,000 Added 46.96%
4,225,000 $37.4 Million
Q3 2023

Nov 14, 2023

BUY
$8.97 - $12.38 $1.48 Million - $2.04 Million
165,000 Added 6.09%
2,875,000 $25.8 Million
Q1 2023

May 15, 2023

BUY
$8.88 - $12.11 $5.13 Million - $6.99 Million
577,261 Added 27.07%
2,710,000 $25.1 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $14.59 $6.72 Million - $9.94 Million
681,538 Added 46.96%
2,132,739 $22.4 Million
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $2.29 Million - $3.55 Million
174,582 Added 13.68%
1,451,201 $26.3 Million
Q2 2022

Aug 15, 2022

SELL
$12.37 - $21.86 $252,347 - $445,944
-20,400 Reduced 1.57%
1,276,619 $18.1 Million
Q1 2022

May 16, 2022

BUY
$15.94 - $23.34 $662,131 - $969,520
41,539 Added 3.31%
1,297,019 $28.5 Million
Q4 2021

Feb 14, 2022

BUY
$14.76 - $24.89 $18.5 Million - $31.2 Million
1,255,480 New
1,255,480 $21.3 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $240M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.